Brief: Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan

MEDINET

21/12/2017 11:01

Dec 21 (Reuters) - Medinet Co Ltd  2370.T : 
    * HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO 
LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF 
NEOCART FOR THE JAPANESE MARKET 
    * HISTOGENICS - TRANSACTION TERMS INCLUDE A $10 MILLION 
UP-FRONT 
PAYMENT WITH A POTENTIAL OF $87 MILLION IN TOTAL MILESTONES, AND 
TIERED ROYALTIES ON SALES 
    * HISTOGENICS - PLANS TO INITIATE PHASE 3 CLINICAL TRIAL IN 
JAPAN 
IN SECOND HALF OF 2018 WITH POTENTIAL COMMERCIALIZATION IN JAPAN 
IN 2021 FOR NEOCART 
 
Source text for Eikon:  ID:nGNXOKDKKa  
Further company coverage:  2370.T  
 
 ((Bangalore.newsroom@thomsonreuters.com;))